CASI PHARMACEUTICALS, INC. — Net Income by Fiscal Year
13 fiscal years, as filed with the SEC; every row links its evidence fact.
Cite as: FACTANKER, https://factanker.com/entity/532f9e4b-2d56-4fd3-b8e8-a4ff01adc884/serie/net-income
| Fiscal year | Net Income | Period | Evidence |
|---|---|---|---|
| FY 2022 | $-41.0M | 2022-01-01 – 2022-12-31 | evidence 0001558370-23-006754 |
| FY 2021 | $-36.7M | 2021-01-01 – 2021-12-31 | evidence 0001558370-22-004437 |
| FY 2020 | $-48.3M | 2020-01-01 – 2020-12-31 | evidence 0001558370-21-003735 |
| FY 2019 | $-46.0M | 2019-01-01 – 2019-12-31 | evidence 0001104659-20-034018 |
| FY 2018 | $-27.5M | 2018-01-01 – 2018-12-31 | evidence 0001104659-20-034018 |
| FY 2017 | $-10.8M | 2017-01-01 – 2017-12-31 | evidence 0001144204-18-017897 |
| FY 2016 | $-9.5M | 2016-01-01 – 2016-12-31 | evidence 0001144204-17-017953 |
| FY 2015 | $-7.2M | 2015-01-01 – 2015-12-31 | evidence 0001144204-16-090485 |
| FY 2014 | $-26.2M | 2014-01-01 – 2014-12-31 | evidence 0001144204-15-018805 |
| FY 2013 | $-5.7M | 2013-01-01 – 2013-12-31 | evidence 0001144204-14-017002 |
| FY 2012 | $-14.5M | 2012-01-01 – 2012-12-31 | evidence 0001144204-13-016578 |
| FY 2011 | $-4.6M | 2011-01-01 – 2011-12-31 | evidence 0001144204-12-013984 |
| FY 2010 | $-8.1M | 2010-01-01 – 2010-12-31 | evidence 0001144204-12-013984 |
Methodology & sources
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
One value per fiscal year (period > 300 days, latest period end per year); fiscal years ending Jun–Dec count toward the ending calendar year, Jan–May toward the prior year. Values as filed (XBRL concept per evidence fact). Source: SEC EDGAR (public domain).
CASI PHARMACEUTICALS, INC. — all facts · Revenue · Operating Income